EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy ( ADT ) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration‐Sensitive Prostate Cancer

Yutaka Yamamoto iD, Saizo Fujimoto, Mamoru Hashimoto iD, Takafumi Minami iD, Wataru Fukuokaya iD, Takafumi Yanagisawa iD, Masanobu Saruta, Atsuhiko Yoshizawa, Yuuki Yoshikawa, Ryoichi Maenosono iD, Takuya Tsujino, Yosuke Hirasawa iD und 5 weitere

International Journal of Urology · 2025

DOI: 10.1111/iju.70202 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift International Journal of Urology, 2025. Verfasst von Yutaka Yamamoto und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Kindai University Nara Hospital, Nara, Japan. Hauptthemen laut MEDLINE: Androgen Antagonists, Prostatic Neoplasms, Castration-Resistant, Androgen Receptor Antagonists, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Evidence on upfront androgen receptor signaling inhibitor (ARSI) plus androgen deprivation therapy (ADT) in the older population with metastatic castration‐sensitive prostate cancer (mCSPC) is scarce. We aimed to compare the oncological outcomes of ARSI plus ADT (upfront doublet therapy) and conventional ADT in mCSPC patients aged ≥ 75 years in a real‐world clinical practice.

Methods

Subjects were mCSPC patients aged ≥ 75 years who received upfront doublet therapy (upfront doublet group) or ADT, either alone or in combination with bicalutamide (conventional ADT group) as a first‐line systemic therapy. Castration‐resistant prostate cancer‐free survival (CRPC‐FS), overall survival (OS), and cancer‐specific survival (CSS) were analyzed. Propensity score matching (PSM) was used to adjust the clinicopathological features.

Results

After PSM, a total of 200 mCSPC patients, 100 in the upfront doublet group and 100 in the conventional ADT group, were included. In the PSM population, median CRPC‐FS was 30.8 months in the upfront doublet group and 12.1 months in the conventional ADT group ( p < 0.05). Median OS was N.A. in the upfront doublet group and 45.2 months in the conventional ADT group ( p < 0.05). Median CSS was also statistically different between the two groups (N.A. vs. 61.6 months; p < 0.05). In subgroup analyses, the upfront doublet group showed improved oncological outcomes in high‐volume disease compared with the conventional ADT group, but not in low‐volume disease.

Conclusions

The oncological benefits of upfront doublet therapy are not diminished in mCSPC patients, even in the older population; but these benefits are limited when restricted to low‐volume disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Androgen AntagonistsProstatic Neoplasms, Castration-ResistantAndrogen Receptor AntagonistsAntineoplastic Combined Chemotherapy ProtocolsHumansMaleAgedAged, 80 and overRetrospective StudiesNitrilesTosyl CompoundsAnilidesTreatment OutcomePropensity Score

Stichwörter der Autor:innen

conventional androgen deprivation therapymetastatic castration‐sensitive prostate cancerolder populationupfront doublet therapy

Substanzen

Androgen AntagonistsbicalutamideNitrilesTosyl CompoundsAnilidesAndrogen Receptor Antagonists

Autor:innen und Institutionen

  • Department of Urology, Kindai University Nara Hospital, Nara, Japan.
  • Department of Urology, Kindai University Hospital, Osaka, Japan.
  • Department of Urology, The Jikei University Hospital, Tokyo, Japan.
  • Department of Urology, Fujita Health University Hospital, Aichi, Japan.
  • Department of Urology, Osaka Medical and Pharmaceutical University Hospital, Osaka, Japan.
  • Department of Urology, Tokyo Medical University Hospital, Tokyo, Japan.

ORCID-Profile: Yutaka Yamamoto, Mamoru Hashimoto, Takafumi Minami, Wataru Fukuokaya, Takafumi Yanagisawa, Ryoichi Maenosono, Yosuke Hirasawa, Takeshi Hashimoto, Takahiro Kimura, Kiyoshi Takahara, Yoshio Ohno

Zitieren

APA

Yamamoto, Y., Fujimoto, S., Hashimoto, M., Minami, T., Fukuokaya, W., Yanagisawa, T., Saruta, M., Yoshizawa, A., Yoshikawa, Y., Maenosono, R., Tsujino, T., Hirasawa, Y., Hashimoto, T., Kimura, T., Takahara, K., Ohno, Y., & Fujita, K. (2025). Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy ( ADT ) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration‐Sensitive Prostate Cancer. International Journal of Urology. https://doi.org/10.1111/iju.70202

Vancouver

Yamamoto Y, Fujimoto S, Hashimoto M, Minami T, Fukuokaya W, Yanagisawa T, et al. Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy ( ADT ) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration‐Sensitive Prostate Cancer. International Journal of Urology. 2025. doi:10.1111/iju.70202

BibTeX
@article{Yamamoto2025,
  author = {Yamamoto, Yutaka and Fujimoto, Saizo and Hashimoto, Mamoru and Minami, Takafumi and Fukuokaya, Wataru and Yanagisawa, Takafumi and Saruta, Masanobu and Yoshizawa, Atsuhiko and Yoshikawa, Yuuki and Maenosono, Ryoichi and Tsujino, Takuya and Hirasawa, Yosuke and Hashimoto, Takeshi and Kimura, Takahiro and Takahara, Kiyoshi and Ohno, Yoshio and Fujita, Kazutoshi},
  title = {Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy ( ADT ) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration‐Sensitive Prostate Cancer},
  journal = {International Journal of Urology},
  year = {2025},
  doi = {10.1111/iju.70202}
}
Kostenlos starten →